AuntMinnie

APRIL 7, 2024

Food and Drug Administration (FDA) later this year to expand the use of its Pluvicto radiopharmaceutical drug to patients with earlier cases of prostate cancer. Patients are required to undergo PSMA-PET scans to determine whether they are eligible for the treatment. Novartis said it will file for a label expansion with the U.S.

PET Scan 52

PET Scan Radiopharmaceuticals IT 52

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Medicare 52

Medicare Nuclear Medicine Radiopharmaceuticals Imaging 52

Imaging Technology

OCTOBER 21, 2024

The first new feature,Centiloid scoring, standardizes the quantification of brain-amyloid plaque in PET scans across three commercially available beta-amyloid PET radiopharmaceuticals used to diagnose Alzheimer’s disease.

Disease 52

Disease Radiopharmaceuticals PET Scan Clinic 52

Imaging Technology

APRIL 28, 2023

This collaboration will drive continuous innovation in molecular imaging agent production to improve access to radiopharmaceuticals in South Africa and help drive precision care in the region.” GE HealthCare has signed an agreement with Axim Life Isotopes South Africa (Pty) Ltd.

Healthcare 98

Healthcare Healthcare Radiopharmaceuticals PET Scan 98

AuntMinnie

JANUARY 19, 2024

Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PET scans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.

Disease 52

Disease Medicare Imaging PET Scan 52

AuntMinnie

OCTOBER 2, 2024

tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image. PET scans predict patient response to Pluvicto.

Digital Imaging and Communications in Medicine 144

Digital Imaging and Communications in Medicine X-ray MRI Hospital 144

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Results demonstrated high detection rates (% positive PET scans) even at low PSA levels.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Open Medscience

MAY 14, 2024

Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.

Imaging 52

Imaging Diagnostic Clinic Nuclear Medicine 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52